IMiA Logo

Prof Adrian Dunlop

Director, Drug & Alcohol Clinical Services, Hunter New England Health

Dr Adrian Dunlop MBBS GdipEpiBiostat (Melb) PhD (UNSW) FAChAM CF is Director and Senior Staff Specialist for Hunter New England Local Health District Drug & Alcohol Clinical Services and Conjoint Professor, School of Medicine and Public Health, College of Health & Wellbeing, University of Newcastle.

He has appointments as an Honorary Medical Officer in Addiction Medicine, to the Justice Health and Forensic Mental Health Network and is a consultant to the Drug & Alcohol Specialist Advisory Service (DASAS), St Vincent’s Local Health Network. He was the Chief Addiction Medicine Specialist, NSW Health (2014-2018) and Clinical Advisor (2012-13) responsible for policy advice in drug and alcohol to the NSW Ministry of Health.

He is a Foundation Fellow of the Australasian Chapter of Addiction Medicine (FAChAM) and current President of the Addiction Medicine Chapter Committee, Royal Australasian College of Physicians. He is a Board Member for the National Clinical Centre for Research on Emerging Drugs (2017-).

He is a Past-President of the Australasian Professional Society on Alcohol and other Drugs (APSAD) 2009-2011, current member of the College of Problems on Drug Dependence (USA), American Society of Addiction Medicine (USA), Society for the Study of Addiction (UK), European Opiate Addiction Treatment Association and Fellow of the International Society for Addiction Medicine (FISAM) and the International Doctors for Healthy Drug Policies.

In 2019 he was awarded the APSAD Senior Scientist Award, was a 2015 James Rankin APSAD orator, and in 2014 was awarded the APSAD Clinician Award. In 2010 he was awarded Clinical Leader of the Year by HNELHD and. In 2005 he was awarded a Churchill Fellowship to investigate the treatment of opiate dependence in pregnancy in Europe and North America.

He has 29 years-experience in the drug and alcohol field, over 360 publications including over 168 peer reviewed journal articles, 9 book chapters, is a co-author on 9 Australian guidelines on drug and alcohol treatment management, including the Clinical Guidelines for the Use of Depot Buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence, funded by NSW Health. He collaborates with various drug and alcohol clinical research groups and clinical sites state across NSW and Australia and is current chair of the NSW Drug and Alcohol Clinical Research Network, a collaboration of NSW public sector drug and alcohol engaged in clinical treatment and research.